Compare BridgeBio Pharma Inc (BBIO) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Canadian National Railway Co. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Canadian National Railway Co. trades at $126.3 (market cap $75.59B). The key difference: Canadian National Railway Co. is far larger — about 4.6× BridgeBio Pharma Inc's market cap, and Canadian National Railway Co. pays a 2.08% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | CNI | |
|---|---|---|
Market Cap | $16.61B | $75.59B |
Sector | Health | Industrials |
52-Week High | $90.17 | $130.58 |
52-Week Low | $47.29 | $90.91 |
Enterprise Value | $18.16B | $91.60B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Canadian National Railway (CNI) trades at $126.60, up 0.16% with neutral technical signals. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation appears elevated at 22.77 P/E. Recent news highlights record grain movements and over 300 customer growth projects across CN's network.
CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 20% upside to consensus price target of $152.38 offers potential, but debt levels rising to 36.61% of assets and competitive pressures warrant caution. Earnings consistency remains key with Q3 results pending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
